Abstract: Agerelated macular degeneration (AMD) is one of the leading causes of blindness in the population aged  50 or more Research progress in the pathogenesis of dry AMD provides many new therapeutic targets. Drugs now under investigation mainly target at inhibition of inflammation, prevention of photoreceptor and retinal pigment epithelium (RPE) loss, decreasing accumulation of toxic byproducts, enhancement of choroid blood supply and ameliorating oxidative stress injury. Besides, stem cell has become a new paradigm for developing therapies for dry AMD.  (Int Rev Ophthalmol, 2013, 37: 361-366)